Is Enovix (ENVX) Still Priced For Growth After Korea Expansion?

Enovix stock has had a difficult run over the past few years, and the current valuation checks lean more expensive than cheap despite that share price pressure. For investors looking at the stock today, the key issue is that recent returns and the market multiple verdict are both challenging, while the overall value score is as low as it gets.

• Over the past 5 years Enovix has declined 79.1%, which means the market has already priced in a lot of disappointment.
• Plans to expand battery manufacturing capacity in South Korea and grow revenue in defense, drone and industrial markets can support the long term story, but leadership changes and ongoing losses highlight execution risk for any valuation case.
• On Simply Wall St's broader checks Enovix scores 0 out of 6 for value, which points to a stock that currently does not screen as a clear bargain.

The issue now is whether Enovix's current share price already reflects these challenges or still builds in expectations that may be hard to meet.

Find out why Enovix's -68.9% return over the last year is lagging behind its peers.

Has Enovix Run Too Far on Sales?

P/S is often the cleaner yardstick for a company like Enovix that is still reporting losses and does not yet have a meaningful P/E ratio to anchor valuation. It lets you compare what investors are paying for each dollar of current sales against other battery and electrical equipment businesses.

Enovix trades on a P/S ratio of about 19.5x, which is well above both the electrical industry average of 2.7x and the peer group average of 6.3x. The Fair Ratio model, which factors in the company’s growth profile, margins, size and risk, suggests a P/S of around 4.8x. The gap between 19.5x and this fair level is large, and the model is heavily penalising Enovix for its current losses and execution risk. That implied fair multiple is better read as a warning flag that the stock screens as very expensive on this framework rather than a precise target.

Despite the recent Korea expansion plans and leadership changes, the P/S multiple still prices Enovix at a rich premium to its industry and peers.

On the P/S multiple, Enovix stock currently screens as overvalued.

See what the numbers say about this price — find out in our valuation breakdown.

The Enovix Narrative: What Would Justify Today's Price?

For Enovix, Simply Wall St Narratives pick up where this valuation puzzle leaves off. They spell out the specific assumptions on future growth, margins and earnings that would need to hold for Enovix's stock to be worth materially more or less than today's price, and they live on Simply Wall St's Community page. Each one treats fair value as a thesis about how the business might perform over time so you can see how that view holds up as new information arrives.

One of the top community narratives on Enovix: 75% undervalued

"Expansion into defense and smart eyewear markets offers promising revenue growth opportunities, driven by compliance and high-margin premium pricing strategies..."

Read one of the top narratives on Enovix

Do you think there's more to the story for Enovix? Head over to our Community to see what others are saying!

The Bottom Line

For Enovix, the current picture is that the stock screens as overvalued on market multiples, with an especially wide gap between its P/S ratio and the fair level suggested by the tailored model. That disconnect reflects how heavily the framework is penalising current losses and execution risk rather than assuming smooth progress. From here, the key question for investors is whether Enovix can deliver on its expansion and commercial ramp strongly enough to justify that premium, or whether the market is already pricing in more than the business can reasonably be expected to deliver.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com